Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP308695.RAk0XV3fHf_5ihiDJu9a225yWUmIiYEQK_Ljn0kHGMeFg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP308695.RAk0XV3fHf_5ihiDJu9a225yWUmIiYEQK_Ljn0kHGMeFg130_assertion type Assertion NP308695.RAk0XV3fHf_5ihiDJu9a225yWUmIiYEQK_Ljn0kHGMeFg130_head.
- NP308695.RAk0XV3fHf_5ihiDJu9a225yWUmIiYEQK_Ljn0kHGMeFg130_assertion description "[The treatment of patients with aggressive lymphomas has improved significantly in recent years, primarily due to the introduction of targeted therapy with the anti-CD20 monoclonal antibody rituximab in combination with chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP308695.RAk0XV3fHf_5ihiDJu9a225yWUmIiYEQK_Ljn0kHGMeFg130_provenance.
- NP308695.RAk0XV3fHf_5ihiDJu9a225yWUmIiYEQK_Ljn0kHGMeFg130_assertion evidence source_evidence_literature NP308695.RAk0XV3fHf_5ihiDJu9a225yWUmIiYEQK_Ljn0kHGMeFg130_provenance.
- NP308695.RAk0XV3fHf_5ihiDJu9a225yWUmIiYEQK_Ljn0kHGMeFg130_assertion SIO_000772 16775878 NP308695.RAk0XV3fHf_5ihiDJu9a225yWUmIiYEQK_Ljn0kHGMeFg130_provenance.
- NP308695.RAk0XV3fHf_5ihiDJu9a225yWUmIiYEQK_Ljn0kHGMeFg130_assertion wasDerivedFrom befree-20140225 NP308695.RAk0XV3fHf_5ihiDJu9a225yWUmIiYEQK_Ljn0kHGMeFg130_provenance.
- NP308695.RAk0XV3fHf_5ihiDJu9a225yWUmIiYEQK_Ljn0kHGMeFg130_assertion wasGeneratedBy ECO_0000203 NP308695.RAk0XV3fHf_5ihiDJu9a225yWUmIiYEQK_Ljn0kHGMeFg130_provenance.